A Phase 1/2 interventional study of PRS-344/S095012 in Solid Tumor, sponsored by Servier Bio-Innovation LLC. Terminated at 11 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Servier Bio-Innovation LLC · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 260 studies in Neoplasm Metastasis with a site in Australia — 60 open to participants now, 106 under way, 34 of them phase 3. Neoplasm Metastasis · Australia.
Among the 260 studies in Neoplasm Metastasis with a site in Australia, this one is the 223rd largest by enrollment of the 253 interventional ones that give a count, is one of 26 that started in 2021, is one of 44 in phase 1/2, and was the 181st registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →60 of the 260 studies in Neoplasm Metastasis with a site in Australia are open now. Recruiting first, the newest first:
BrYet US, Inc. · Sites in Australia
Ages 18+
BeOne Medicines · Sites in Australia, New Zealand
Ages 18+
Second Life Therapeutics · Sites in Australia
Ages 18+
Eilean Therapeutics · Sites in Australia, Uzbekistan
Ages 18+
Immuneering Corporation · Sites in Australia, United States, Georgia and 6 more countries
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
260 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 111 · Phase 2 101 · Phase 3 91 · Phase 4 1
First in 1996; this study’s year is marked. 26 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is close to the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 227 across the 253 interventional studies, 1,263 across the 2 observational. Of the 145 that completed or were terminated, 77 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
227 of 260 have an industry lead sponsor. The 10 most frequent:
Servier Bio-Innovation LLC is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Servier Bio-Innovation LLC has 2 studies filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
31 of the studies in Neoplasm Metastasis with a site in Australia that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06103864Phase 3AstraZenecaA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | 2027-07-28 |
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT05544552Tyra Biosciences, IncSafety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | 2026-11 |
Add all 31 to your calendar (.ics) → With an account.
Among the 260 studies in Neoplasm Metastasis with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a first-in-human (FIH), phase 1/2, multi center, open-label, dose escalation and cohort expansion study designed to determine the safety and tolerability of PRS-344/S095012 in patients with advanced and/or metastatic solid tumors.
The trial is an open-label, multi-center safety trial of PRS-344/S095012. The trial consists of two parts, a dose escalation part (phase 1, first-in-human (FIH) and an expansion part (phase 2)). The expansion part of the trial will be initiated once the optimal biological dose (OBD) has been determined. The study was terminated during phase 1 and thus, recruitment into phase 2 was not started.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who have received prior:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PRS-344/S095012
Drug: PRS-344/S095012
PRS-344/S095012 Monotherapy or with pretreatment by obinutuzumab
Safety Measurements: Number of Participants With at Least One DLT in the First 28-days of Treatment
Phase 1: Dose-limiting toxicities (DLTs) over the first 28-days of study treatment
Time frame: 28 days
Safety Measurements: Number of Participants With at Least One AE
Phase 1: Adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
Time frame: Through study termination, approximately 3.5 years
Safety Measurements: Number of Participants With at Least One AE Leading to Treatment Discontinuation
Phase 1: Discontinuation of study treatment due to an AE
Time frame: Through study termination, approximately 3.5 years
Mean PRS-344/S095012 Concentrations at the End of the Infusion
Phase 1
Time frame: Cycle 1 Day 1 and Cycle 2 Day 1 (each cycle was 28 days)
Mean PRS-344/S095012 Trough Concentrations (Ctrough)
Phase 1
Time frame: Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15, Cycle 3 Day 1, Cycle 3 Day 15, Cycle 4 Day 1, Cycle 4 Day 15, Cycle 5 Day 1, Cycle 5 Day 15, Cycle 6 Day 1 (each cycle was up to 28 days)
Number of Participants With at Least One Positive Anti-drug Antibody (ADA) Titer Result PRS-344/S095012
Phase 1
Time frame: Through study termination, approximately 3.5 years
Objective Response Rate (ORR)
Phase 1: Defined as Complete Response (CR) plus Partial Response (PR), per investigator assessment
Time frame: Through study termination, approximately 3.5 years
Best Overall Response (BOR)
Phase 1: The best response across visits as; 1) partial response (PR): At least 2 PR or better (PR followed by PR or PR followed by CR) at least 4 weeks apart and not qualifying for a complete response (CR), 2) stable disease (SD): At least 1 SD assessment (or better) ≥ 43 days (assuming an 8-week scan interval with a 14-day visit window) after start of study treatment and not qualifying for CR or PR, 4) progressive disease (PD): Documentation of PD after start of study treatment (and not qualifying for CR, PR, or SD), 5) non-evaluable (NE): All other cases.
Time frame: Through study termination, approximately 3.5 years
Best Tumor Shrinkage From Baseline
Phase 1: The best shrinkage value for the target lesion from baseline
Time frame: Through study termination, approximately 3.5 years
| Milestone | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab |
|---|---|---|---|---|---|
| Started | 4 | 9 | 14 | 6 | 13 |
| Completed | 0 | 0 | 0 | 2 | 0 |
| Not completed | 4 | 9 | 14 | 4 | 13 |
| Withdrew: Withdrawal of consent | 0 | 2 | 0 | 1 | 1 |
| Withdrew: Death due to progressive disease | 2 | 5 | 12 | 2 | 6 |
| Withdrew: Death due to other causes | 1 | 0 | 2 | 1 | 2 |
| Withdrew: Other | 1 | 2 | 0 | 0 | 4 |
Phase 1: Dose-limiting toxicities (DLTs) over the first 28-days of study treatment
| Participants | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab |
|---|---|---|---|---|---|
| Safety Measurements: Number of Participants With at Least One DLT in the First 28-days of Treatment | 0 | 1 | 3 | 1 | 3 |
Phase 1: Adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
| Participants | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab |
|---|---|---|---|---|---|
| Safety Measurements: Number of Participants With at Least One AE | 4 | 9 | 14 | 6 | 12 |
Phase 1: Discontinuation of study treatment due to an AE
| Participants | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab |
|---|---|---|---|---|---|
| Safety Measurements: Number of Participants With at Least One AE Leading to Treatment Discontinuation | 1 | 4 | 7 | 2 | 7 |
Phase 1
| ng/mL | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 3703.3 ± 1627.2 | 10169.3 ± 1222.7 | 18843.0 ± 4836.7 | 22022.9 ± 3533.0 | 9884.4 ± 2245.4 |
| Cycle 2 Day 1 | 2542.7 ± 1963.5 | 5927.5 ± 3534.7 | 8961.4 ± 10780.9 | 12292.2 ± 8914.1 | 8118.0 ± 2319.4 |
Phase 1
| ng/mL | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab |
|---|---|---|---|---|---|
| Cycle 1 Day 1 | 0.0 ± 0.0 | 0.0 ± 0.0 | 2.3 ± 8.6 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Cycle 1 Day 15 | 0.0 ± 0.0 | 0.0 ± 0.0 | 2.5 ± 5.0 | 6.3 ± 6.2 | 64.7 ± 191.4 |
| Cycle 2 Day 1 | 0.0 ± 0.0 | 0.9 ± 2.2 | 1.1 ± 3.2 | 0.0 ± 0.0 | 2.9 ± 7.1 |
| Cycle 2 Day 15 | 0.0 ± 0.0 | 1.3 ± 2.9 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Cycle 3 Day 1 | 0.0 ± 0.0 | 3.0 ± 5.9 | 0.0 ± 0.0 | 0.0 | 0.0 ± 0.0 |
| Cycle 3 Day 15 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 | 0.0 |
| Cycle 4 Day 1 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 | 0.0 ± 0.0 |
| Cycle 4 Day 15 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 | — | 0.0 |
| Cycle 5 Day 1 | — | 0.0 ± 0.0 | 0.0 | — | 0.0 |
| Cycle 5 Day 15 | — | 0.0 ± 0.0 | 0.0 | — | 0.0 |
| Cycle 6 Day 1 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 | — | 0.0 |
Phase 1
| Participants | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab |
|---|---|---|---|---|---|
| Number of Participants With at Least One Positive Anti-drug Antibody (ADA) Titer Result PRS-344/S095012 | 3 | 8 | 10 | 4 | 2 |
Phase 1: Defined as Complete Response (CR) plus Partial Response (PR), per investigator assessment
| Percentage of participants | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 0 (0 to 49.0) | 0 (0 to 32.4) | 0 (0 to 21.5) | 0 (0 to 39.0) | 10.0 (1.8 to 40.4) |
Phase 1: The best response across visits as; 1) partial response (PR): At least 2 PR or better (PR followed by PR or PR followed by CR) at least 4 weeks apart and not qualifying for a complete response (CR), 2) stable disease (SD): At least 1 SD assessment (or better) ≥ 43 days (assuming an 8-week scan interval with a 14-day visit window) after start of study treatment and not qualifying for CR or PR, 4) progressive disease (PD): Documentation of PD after start of study treatment (and not qualifying for CR, PR, or SD), 5) non-evaluable (NE): All other cases.
| Participants | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab |
|---|---|---|---|---|---|
| PR | 0 | 0 | 0 | 0 | 1 |
| SD | 4 | 3 | 2 | 1 | 3 |
| PD | 0 | 4 | 8 | 3 | 5 |
| NE | 0 | 2 | 4 | 2 | 3 |
Phase 1: The best shrinkage value for the target lesion from baseline
| mm | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab |
|---|---|---|---|---|---|
| Best Tumor Shrinkage From Baseline | 104.5 ± 150.05 | 102.5 ± 67.24 | 115.3 ± 107.91 | 78.3 ± 86.05 | 94.1 ± 68.68 |
Collected over Through study termination, approximately 3.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PRS-344/S095012 12mg | 3/4 (75%) | 1/4 (25%) | 4/4 (100%) |
| PRS-344/S095012 36mg | 5/9 (55.6%) | 8/9 (88.9%) | 9/9 (100%) |
| PRS-344/S095012 60mg | 14/14 (100%) | 12/14 (85.7%) | 14/14 (100%) |
| PRS-344/S095012 80mg | 3/6 (50%) | 3/6 (50%) | 6/6 (100%) |
| PRS-344/S095012 36mg and Obinutuzumab | 8/13 (61.5%) | 11/12 (91.7%) | 12/12 (100%) |
| Event | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab |
|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 2/9 | 5/14 | 0/6 | 4/12 |
| Cytokine release syndromeImmune system disorders | 0/4 | 1/9 | 4/14 | 1/6 | 1/12 |
| Drug-induced liver injuryHepatobiliary disorders | 0/4 | 0/9 | 0/14 | 0/6 | 3/12 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/4 | 0/9 | 2/14 | 0/6 | 0/12 |
| Abdominal compartment syndromeGastrointestinal disorders | 0/4 | 0/9 | 0/14 | 1/6 | 0/12 |
| Intestinal obstructionGastrointestinal disorders | 0/4 | 1/9 | 0/14 | 1/6 | 0/12 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/4 | 0/9 | 0/14 | 1/6 | 0/12 |
| Hepatic failureHepatobiliary disorders | 0/4 | 1/9 | 0/14 | 1/6 | 1/12 |
| Haemophagocytic lymphohistiocytosisImmune system disorders | 0/4 | 0/9 | 1/14 | 1/6 | 0/12 |
| Bacterial sepsisInfections and infestations | 0/4 | 0/9 | 0/14 | 1/6 | 0/12 |
| Event | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/4 | 1/9 | 3/14 | 1/6 | 0/12 |
| NauseaGastrointestinal disorders | 0/4 | 2/9 | 3/14 | 4/6 | 5/12 |
| FatigueGeneral disorders | 2/4 | 3/9 | 9/14 | 3/6 | 7/12 |
| Abdominal painGastrointestinal disorders | 2/4 | 1/9 | 0/14 | 1/6 | 1/12 |
| PyrexiaGeneral disorders | 1/4 | 3/9 | 7/14 | 1/6 | 3/12 |
| Aspartate aminotransferase increasedInvestigations | 2/4 | 3/9 | 4/14 | 0/6 | 1/12 |
| Night sweatsSkin and subcutaneous tissue disorders | 2/4 | 0/9 | 2/14 | 1/6 | 0/12 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/4 | 4/9 | 3/14 | 2/6 | 2/12 |
| Decreased appetiteMetabolism and nutrition disorders | 0/4 | 1/9 | 4/14 | 1/6 | 5/12 |
| Abdominal distensionGastrointestinal disorders | 0/4 | 1/9 | 1/14 | 2/6 | 0/12 |
| Age, Continuous(years) | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab | Total |
|---|---|---|---|---|---|---|
| Mean | 55.0 ± 10.10 | 62.2 ± 8.81 | 59.4 ± 14.67 | 53.8 ± 8.84 | 62.7 ± 13.28 | 59.8 ± 12.21 |
| Age, Customized(Participants) | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab | Total |
|---|---|---|---|---|---|---|
| <65 years | 3 | 5 | 7 | 6 | 7 | 28 |
| ≥65 years | 1 | 4 | 7 | 0 | 6 | 18 |
| Sex: Female, Male(Participants) | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 5 | 9 | 3 | 3 | 21 |
| Male | 3 | 4 | 5 | 3 | 10 | 25 |
| Race and Ethnicity Not Collected(Participants) | PRS-344/S095012 12mg | PRS-344/S095012 36mg | PRS-344/S095012 60mg | PRS-344/S095012 80mg | PRS-344/S095012 36mg and Obinutuzumab | Total |
|---|---|---|---|---|---|---|
| Count of participants | — | — | — | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: After Marketing Authorization in EEA or US if the study is used for the approval.
Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.
Data sharing details ↗ · clinicaltrials.servier.com
Ran from Sep 2021 to primary completion in Apr 2025, 42 months.
Results were first posted in Jun 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Servier Bio-Innovation LLC